Market Access

Speed formulary acceptance by demonstrating value

Increasingly complex healthcare systems and more demanding stakeholders require comprehensive resources and support. Quintiles combines strategic thinking with clinical expertise to effectively demonstrate real-world outcomes, but we don't stop there. Our reach extends to teams in the field who connect with payers on a local level to communicate your product value story.

banner_team at board

Access to 60M de-identified EHRs

Quintiles has access to 60M de-identified Electronic Health Records used in trial design since 2004.

It’s never too soon to devise your market access strategy

Validate product value and accelerate approval more effectively with early development of your strategic approach. Success depends on collecting the best data to demonstrate potential outcomes and knowing the key stakeholders in each market, the exact time to engage with them and the relevant data that each requires.

Connecting clinical insight with commercialization experience

As healthcare systems become more complex and payers' influence becomes more prominent, Quintiles can help you create and implement an integrated market access strategy to successfully target your message, gain adoption on formularies, and negotiate better pricing and reimbursement.

Our experts work with you during clinical development to map out appropriate disease profiles and plan market implementation. By understanding the diverse needs of all audiences, we collect the right kinds of evidence required to present compelling value and outcomes data to each stakeholder. This integrated approach enables you to confidently illustrate how your new product and desired price compare with existing treatments, which will demonstrate the additional value that justifies your price point.

Throughout the process, you gain access to important data, key stakeholders and indispensable market awareness. This includes:

  • A global network of regulatory experts sitting in-market, with existing relationships to decision makers in the healthcare system.
  • Access to an up-to-date global repository of published HTA Watch reports from nearly 100 agencies in 32 countries.
  • Approximately 400 real-world and late phase programs, involving more than 44,000 sites and 9 million patients in approximately 100 countries, between 2010 and 2012 alone.
  • More than 175 patient registries and observational studies, involving more than 30,000 sites and 9 million patients in more than 90 countries.
  • More than 90 Phase IIIB studies and 120 Phase IV studies, involving more than 13,000 sites and 240,000 patients in more than 70 countries.

The power of possibilities

Related services

Real-world Data & Analytics
Accelerate Adoption & Adherance
Regulatory Affairs
Case Study Jun 08, 2010
Read more